These designations mean the system can be sold in the US and Europe for use in laboratory-developed tests including, for instance, protein-based diagnostics.
The company posted revenues of $500.6 million, up from $493.2 million in Q3 2014. Currency effects contributed to a roughly 7 percent reduction in sales growth.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.
The conference was relatively light on new mass spec launches, with many vendors focusing instead on more targeted applications of existing technology.
The amendment to a 2013 debt financing agreement will increase revolving commitments to $1.3 billion, extend maturity of loans, and adjust interest rates and fees.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.
